Plaque Psoriasis

These new findings suggest the need for expansion of JAK1/JAK2 targeting approaches for treatment of eosinophilic cellulitis and other types of eosinophilic disease.

This new data emphasizes the vital importance of timely detection and effective treatment for squamous cell carcinomas in this particular population.

This new tool, using an automated analysis of different parts of the body, could help clinicians to address previously unmet needs for treatment in conditions such as psoriasis.

These new guidelines were developed to benefit younger patients with inflammatory skin diseases, and may be helpful given the inexpensive nature and general availability of the drug.

In this episode of MEDcast, expert dermatologists discuss exciting advancements in systemic therapies such as JAK inhibitors, and the latest breakthroughs in topical treatments for plaque psoriasis

In this episode of MEDcast, expert dermatologists discuss exciting advancements in systemic therapies such as JAK inhibitors, and the latest breakthroughs in topical treatments for plaque psoriasis.

This new research may help clinicians in their guidance of patients with T21, though the data may require future studies to help examine immune parameters of the clinical outcomes.

Statistically significant reductions in erythema, scaling, thickness, and overall target plaque scores were observed in both treatment regimens.

During the next part of his Q&A interview, Dr. Lebwohl further described new and future research into treating psoriasis.

This Q&A interview with Dr. Lebwohl featured a discussion about which therapies may be the best for patients who have psoriasis.

Alopecia areata patients had higher rates of diseases including psoriasis, allergic rhinitis, asthma, and atopic dermatitis, highlighting the burden of comorbidities on patients in the US.

This research indicates biologics may be safe for women of childbearing age, to whom they are often prescribed, as they pose an acceptable risk to fetuses/neonates.

Early intervention was shown to lead to better clinical responses, results which could translate to long-term improvements in psoriasis and sustained maintenance of response after withdrawal.

In the results of this final analysis, the hidradenitis suppurativa drug was found to be well tolerated in patients regardless of either differing demographics or clinical characteristics.

These 4 treatments and their biosimilars show no significant differences, though future studies may be necessary to assess long-term efficacy and safety of biosimilars in treating psoriasis.

This new research into psoriasis and its systemic effects and comorbidities may be used to identify the mechanisms which affect skin inflammation in a single area and effects on other organs.

Gain-of-function STAT4 variants in patients with disabling pansclerotic morphea suggest a potential therapeutic role for JAK inhibition, resulting in improved clinical symptoms and inflammatory markers.

In this segment of her interview, Dr. Arkin was asked about news, recent research, and therapies for patients with scleroderma, in honor of National Scleroderma Awareness Month.

This interview with Dr. Arkin involved a discussion, in honor of June being National Scleroderma Awareness Month, of information on underlying causes and new research on the skin condition.

New prognostic model enhances methotrexate monitoring for immune-mediated inflammatory diseases.

New data indicating this connection suggests a need for clinicians to take into account cardiovascular examination for patients with both the skin disorder and symptoms suggestive of incident venous thromboembolism.

This research was conducted to identify distinct subgroups of those with atopic dermatitis, and the findings may help to promote better counseling and treatment options.

Those with higher psoriasis severity was associated with a higher improvement in anxiety/depression at the second timepoint.

Recent research from Japan indicates that there are several comorbidities identified for patients with psoriasis, raising awareness of incidental findings in CT analysis.

New data indicates that psoriasis patients who are naïve to biological therapies may benefit from early intervention with secukinumab, though further research is needed.